Orforglipron
A once-a-day pill that does what the GLP-1 shots do: less appetite, steadier blood sugar, about 12 percent off. No needle at all.
What it is
Orforglipron gives you the GLP-1 effect, feeling full sooner and thinking about food less, in a daily tablet you can take with or without food. Expect roughly a tenth of your body weight gone over a year if you take it as prescribed; less than tirzepatide, with no injection and no fridge.
It is for people who want a GLP-1 but will not inject, or who are tired of weekly shots and refrigeration, or who want to switch to something simpler after losing weight on an injectable. Being a small molecule rather than a peptide, it is cheap to make and does not need the fasting-and-water ritual of oral semaglutide (Rybelsus): you take it whenever, with food or without. It was FDA-approved in April 2026 as Foundayo (Eli Lilly) for chronic weight management, which makes it a prescription you fill at a pharmacy, not a vial from a research vendor.
Appetite drops within the first week or two at the starting dose and gets stronger with each step up. Weight loss in the main trial averaged about 12.4 percent at the top dose over the study, with most of it in the first six to nine months, then a plateau. Good looks like losing one to two pounds a week early on without white-knuckling it, and portions shrinking on their own. It will not do much for someone who keeps eating past fullness, and it does nothing for muscle; protein and lifting are on you.
You titrate, no exceptions. Start at 1 mg once a day and step up roughly every four weeks through the label doses to a maintenance dose of 6, 12 or 36 mg, stopping wherever appetite control and side effects balance; 12 mg is a common landing point and 36 mg is the top. Pick a time of day and keep it. The mistake people make is jumping steps to get there faster, which buys nausea and vomiting, or stopping at the first queasy week instead of holding the dose until it settles. Constipation is the quiet one; water, fibre and walking handle it.
The evidence is as solid as it gets on this site. The phase 3 ATTAIN program, published in NEJM and The Lancet, tested it in thousands of people with obesity and with type 2 diabetes and hit its weight, blood sugar and heart-risk endpoints. The honest comparison: about 12.4 percent at the top dose against roughly 15 percent for injectable semaglutide and 20 percent or more for tirzepatide. You trade some effect for the convenience of a pill.
If you are fine with a weekly shot and want maximum weight loss, tirzepatide beats it clearly, and retatrutide is ahead in trials. If you already take oral semaglutide and the fasting routine does not bother you, there is no strong reason to switch. Skip it, like every GLP-1, if you or your family have had medullary thyroid cancer or MEN 2, if you have had pancreatitis, or if you are pregnant or planning to be. And because it is a real prescription drug, anything sold as orforglipron powder by a research vendor is a product with no label and no way to check the dose.
What people use it for
Weight loss
Most evidenceThe ATTAIN-1 phase 3 trial in over 3,000 adults with obesity showed about 12.4 percent average weight loss at the top dose, with the expected improvements in waist, blood pressure and lipids. That is below tirzepatide and near older semaglutide data, in a once-daily pill, and it is the basis for the FDA approval.
Type 2 diabetes
Most evidenceIn ATTAIN-2, people with obesity and type 2 diabetes lost weight and lowered their HbA1c on orforglipron, and separate diabetes trials have been run. Weight management is the approved use so far; diabetes use follows the label as it expands.
Keeping weight off after an injectable
Some evidenceLilly has studied switching people from injectable GLP-1s to orforglipron to hold their weight loss. That is the use many people are most interested in, and it is a sensible one given the shared mechanism, but check the current label for whether it is formally covered.
Sleep apnea and blood pressure
Early daysLike other GLP-1s it is being studied for obstructive sleep apnea and high blood pressure, where the benefit mostly tracks the weight loss. These are investigational uses unless separately approved.
How people use it
Safety, in brief
Things people sometimes notice
- Nausea, mostly in the week after each dose increase
- Constipation, or sometimes diarrhoea
- Feeling full after very little, and some food aversion
- Burping and reflux
The full picture — stop signs and who should talk to a doctor first — is on the dosing guide.
Sources
The labels and studies behind this page. Each link opens the original on PubMed, DailyMed or ClinicalTrials.gov.
- Foundayo (orforglipron) prescribing information
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
- Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial
- Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial